

Cornea Update

DALK & Endothelial Keratoplasty

Sheraz Daya
MD FACP FRCS(Ed) FRCOphth



DEEP ANTERIOR LAMELLAR KERATOPLASTY



Indications for Lamellar Keratoplasty

"WHENEVER THE ENDOTHELIUM IS NORMAL"




Anterior Lamellar Keratoplasty

- **Advantages**
 - Retains endothelium
 - Reduces risk of corneal blindness
- **Disadvantages (previously)**
 - Poor Vision
 - Interface opacification
 - Regular and Irregular Astigmatism
 - Technical skill
 - Perforation



DALK – Why ?

- "Primo No Nocere"
- SAFETY
- SURVIVAL – long term
- OTHER...



PK can be HAZARDOUS !!!



PK – Hazards...

- Explosive Choroidal Haemorrhage 0.56*-1%
- Rejection & Failure
- Reduced survival of Regrafts
- Glaucoma 19- 30%
- Cataract
- Endophthalmitis

* Speaker MG, Gueniano PN, Met JA, Coal CT, Berger A, Marmor M. A case-control study of risk factors for intraoperative suprachoroidal explosive hemorrhage. *Ophthalmology* 1991 Feb;98(2):202-9.



PK – long term...

EXTENDED REPORT																															
Penetrating keratoplasty: outcomes from a corneal unit compared to national data																															
P Beckingsole, I Mavrikakis, N Al-Yousif, E Mavrikakis, S M Daya																															
<i>Br J Ophthalmol</i> 2006;90:729-731. doi: 10.1136/bjophthalmol.2005.084272																															
Table 1 Three year graft survival rates for national outcome data (UKT) and Queen Victoria Hospital (QVH)																															
<table border="1"> <thead> <tr> <th>Diagnosis</th> <th>UKT 3 year graft survival rates (%)</th> <th>QVH 3 year graft survival rates (%)</th> <th>p Value</th> </tr> </thead> <tbody> <tr> <td>Keratoconus</td> <td>93</td> <td>98</td> <td>0.019</td> </tr> <tr> <td>PBK</td> <td>62</td> <td>92</td> <td>0.00003</td> </tr> <tr> <td>Fuchs' dystrophy</td> <td>87</td> <td>90</td> <td>0.47</td> </tr> <tr> <td>Viral keratitis</td> <td>77</td> <td>84</td> <td>0.002</td> </tr> <tr> <td>Regrafts</td> <td>57</td> <td>67</td> <td>0.002</td> </tr> <tr> <td>Total</td> <td>79</td> <td>81</td> <td>0.15</td> </tr> </tbody> </table>				Diagnosis	UKT 3 year graft survival rates (%)	QVH 3 year graft survival rates (%)	p Value	Keratoconus	93	98	0.019	PBK	62	92	0.00003	Fuchs' dystrophy	87	90	0.47	Viral keratitis	77	84	0.002	Regrafts	57	67	0.002	Total	79	81	0.15
Diagnosis	UKT 3 year graft survival rates (%)	QVH 3 year graft survival rates (%)	p Value																												
Keratoconus	93	98	0.019																												
PBK	62	92	0.00003																												
Fuchs' dystrophy	87	90	0.47																												
Viral keratitis	77	84	0.002																												
Regrafts	57	67	0.002																												
Total	79	81	0.15																												



DALK - Techniques

- Injection of air into the stroma – big bubble
- Injection of water / viscoelastics
- Stromal Air Injection
- Ferrara Ring Dissection
- Optical recognition - Melles
- Modification of Melles's technique





'DALK and Endothelial Keratoplasty' (slides 1-16)

Sheraz Daya
MD FACP FRCS(Ed) FRCOphth

DALK – How ?

- Descemet's
 - Big Bubble – Anwar
 - Viscodissection
- Pre-Descemet's
 - Optical Recognition – Melles
- Femtosecond Assisted

CENTRE
FOR
SIGHT


Deep Anterior Lamellar Keratoplasty

Sheraz Daya MD

www.centrefoights.com

CENTRE
FOR
SIGHT

Do Lamellars Reject ?



Epithelial Rejection



Sub-epithelial Rejection

CENTRE
FOR
SIGHT

DALK vs PK for Keratoconus

Authors	Number of eyes	BCVA > 20/40	BCVA > 20/30
<i>Deep Anterior Lamellar Keratoplasty for keratoconus</i>			
This study	50	74.2%	56%
coombes et al. ⁴	37	80%	64%
Watson et al. ⁵	25	87.5%	N/A
Anwar et al. ¹	181	89%	27%
Funnel et al. ⁶	20	76%	N/A
<i>Penetrating Keratoplasty for keratoconus</i>			
Buzard et al. ⁷	104	88%	88%
Lim et al. ⁸	93	87%	N/A
Watson et al. ⁵	22	95%	N/A
Funnel et al. ⁶	20	85%	N/A

CENTRE
FOR
SIGHT

Indications for Lamellar Keratoplasty

- "WHENEVER THE ENDOTHELIUM IS NORMAL"

CENTRE
FOR
SIGHT

POSTERIOR LAMELLAR KERATOPLASTY

CENTRE
FOR
SIGHT

POSTERIOR LAMELLAR KERATOPLASTY

- ENDOTHELIAL FAILURE
- Cornea Oedema
 - Fuchs Endothelial Dystrophy
 - Pseudophakic Bullous Keratopathy
 - ICE Syndrome – endothelial failure

CENTRE
FOR
SIGHT


FUCHS DYSTROPHY

CENTRE
FOR
SIGHT

'DALK and Endothelial Keratoplasty'

(slides 17-32)

Pseudophakic Bullous Keratopathy



S CENTRE FOR SIGHT

Endothelial Failure

- Traditional approach = Penetrating keratoplasty
- Problems
 - Sutures & suture related problems
 - Rehabilitation – 1 year approx
 - Frequent follow up
 - Open-sky – hazardous
 - Astigmatism – regular & irregular

Brian Davis, M.D., Cataract & EYEMAGNIFICATION

S CENTRE FOR SIGHT

Endothelial Failure

- Why not just replace the endothelial layer ?
 - Anterior corneal stroma is normal
 - Smaller incision outside cornea
 - Less astigmatism
 - More rapid rehabilitation
- CHALLENGE:
 - Keep the endothelial cells in place
 - Graft survival

S CENTRE FOR SIGHT



S CENTRE FOR SIGHT



S CENTRE FOR SIGHT

S CENTRE FOR SIGHT



S CENTRE FOR SIGHT

DSAEK ISSUES

- DISLOCATION
 - Good air Fill
 - No Healon
 - Technique
- ENDOTHELIAL FAILURE
 - Technique



S CENTRE FOR SIGHT

DSAEK ISSUES

- ENDOTHELIAL FAILURE - avoidance
 - Young Donor preferable
 - Single point fixation of Folded Donor
 - Increase Incision size



S CENTRE FOR SIGHT

Descemet's Membrane Endothelial Keratoplasty (DMEK)



S CENTRE FOR SIGHT

INTRALASE and Corneal Grafting




S CENTRE FOR SIGHT

Intralase & Corneal Grafts

- Intralase Femtosecond Laser
 - CE marked for making PRECISE cuts in corneal tissue
 - Principally used for Flap creation in Lasik
 - Applications in Grafting
 - Anterior Lamellar Keratoplasty
 - Posterior Lamellar Keratoplasty (DSIEK)
 - Penetrating Keratoplasty

S CENTRE FOR SIGHT

INTRALASE™ Photodisruption



S CENTRE FOR SIGHT

Anterior Lamellar Keratoplasty



S CENTRE FOR SIGHT

LAMELLAR GRAFTS

- Anterior Basement Membrane Dystrophy – Familial




S CENTRE FOR SIGHT

HISTOLOGY



S CENTRE FOR SIGHT



S CENTRE FOR SIGHT


'DALK and Endothelial Keratoplasty (slides 33-48)

Sheraz Daya
MD FACP FRCS(Ed) FRCOphth

RESULTS

- BSCVA


– One eye = Amblyopic (improved from 20/200 to 20/100) excluded



© Centre for Sight


RESULTS

- BSCVA - lines gained /lost



© Centre for Sight

RESULTS - Keratometric Astigmatism




© Centre for Sight

Complications

- Compression Striae -recovered following suture removal
- Replacement in one case
 - Polyopia and high astigmatism (graft oversized)
- Residual refractive error
 - May need supplemental LASIK

© Centre for Sight

GEOMETRIC PATTERNS - I




© Centre for Sight

GEOMETRIC PATTERNS - II

- "Tongue & Groove" !



Zigzag



Christmas Tree



Zig Square

•STABLE - no OVER or UNDER riding
•ANTERIOR ANGLE (ZIG) = smooth anterior join / surface


© Centre for Sight

Femtosecond PK




© Centre for Sight

No 6 button









ZIG- SQUARE (recipient button)



Electron microscopy performed at St.Thomas's Hospital - John Marshall PhD

© Centre for Sight

CENTRE
FOR
SIGHTCENTRE
FOR
SIGHTCENTRE
FOR
SIGHTCENTRE
FOR
SIGHTCENTRE
FOR
SIGHTCENTRE
FOR
SIGHTCENTRE
FOR
SIGHT


- Penetrating Keratoplasty
- INDUSTRY Involvement
 - Improved biomechanical strength
 - Inverse cut
 - Tophat cuts
 - Better astigmatic outcomes

CENTRE
FOR
SIGHT

'DALK and Endothelial Keratoplasty'


(slides 49-54)

FEMTOSECOND DALK



S CENTRE FOR SIGHT

FSDALK – Donor Preparation



S CENTRE FOR SIGHT


FSDALK - Recipient



FSDALK Recipient
Sheraz Daya

S CENTRE FOR SIGHT

Postoperative 6 weeks



S CENTRE FOR SIGHT

Conclusion

- Selective Keratoplasty
 - Superficial Anterior Lamellar Keratoplasty
 - Microkeratome
 - Femtosecond Laser
 - Deep Anterior Lamellar Keratoplasty
 - Manual
 - Big bubble
 - Femtosecond laser

S CENTRE FOR SIGHT

Thank you

S CENTRE FOR SIGHT

Dry Eye Update

Dry Eye - Our approach...

Sheraz Daya
MD FACP FRCS(Ed) FRCOphth



Dry Eye - Our Approach



SHERAZ DAYA

MD FACP FRCS(Ed) FRCOphth

**CENTRE
FOR
SIGHT**

Financial Disclosure

Company	Code	Definitions
1. Abbott Medical Optics Inc.	S	C = Consultant / Advisor
2. Allergan	L	E = Employee
3. Bausch + Lomb	C,L	I = Lecture Fees
4. Carl Zeiss Meditec	C	O = Equity Owner
5. Clavista	C	P = Patents / Royalty
6. Ellex	L	S = Grant Support
7. Excellens	C, O	
8. Lincor Biosciences	C	
9. Lumenis	C	
10. Medicem	C	
11. Nidek, Inc.	C,L	
12. Omeros	C	
13. Physiol	L	
14. PRN	O	
15. STAAR Surgical	C,O	
16. Strataspey Crown	C	
17. Scope Pharmaceuticals	C	
18. Rayner	C	


**CENTRE
FOR
SIGHT**

TFOS II

"Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles."


**CENTRE
FOR
SIGHT**

Stable Tear Film Maintenance




**CENTRE
FOR
SIGHT**

OCULAR SURFACE RELATIONSHIPS




**CENTRE
FOR
SIGHT**

DRY EYE



**CENTRE
FOR
SIGHT**



**CENTRE
FOR
SIGHT**

My approach to Dry Eye

- History
- Diagnosis
- Management
 - Emphasis on Evaporative Dry Eye

2007 DEWS REPORT:

"Meibomian gland dysfunction is a condition of meibomian gland obstruction and is the most common cause of evaporative dry eye."

**CENTRE
FOR
SIGHT**

'Dry Eye - Our approach...' (slides 1-16)

Sheraz Daya
MD FACP FRCS(Ed) FRCOphth



HISTORY

- Symptoms
 - Grittiness
 - Burning
 - Itching
 - Lid stuck to eye on awakening
 - Photophobia
 - Eye Fatigue
 - Excessive Tearing (windy environment)
- Drugs

CENTRE FOR SIGHT

Questionnaires

- SPEED
- OSDI
- Useful for subjective scoring
- Interval change
- Content – serves as a guide to type of dry eye



CENTRE FOR SIGHT

Clinical Evaluation

- Lid Closure
- Blink Rate
- Puncti
- LID MARGINS
 - Collarettes – scurf, basal, sleeves
 - Meibomian Gland orifices
 - Meibum quality
 - Level of inflammation



CENTRE FOR SIGHT

CLINICAL EVALUATION


- CONJUNCTIVA
 - Bulbar
 - Palpebral
- FLUORESCINE
 - Lid "Wiper" Action
 - Quality of tear surface
 - Tear Meniscus
 - Corneal & Conjunctival Stain
- Rose Bengal / Lissamine Green




CENTRE FOR SIGHT

Evaporative DED accounts for 86% of DED

The number of Meibomian glands is relatively small, any dropout has a significant impact



CENTRE FOR SIGHT



CENTRE FOR SIGHT
Sheraz Daya MD




CENTRE FOR SIGHT

'Dry Eye - Our approach...' (slides 17-32)

ANTARES

- Tear break up time
- Meibography



TearScience® Solution



CENTRE
FOR
SIGHT

TearLab® Osmolarity System



CENTRE
FOR
SIGHT

What does the TearLab system measure?

Blinking, aqueous tearing (mixing), increased lipid secretion excretion - all lower osmolarity transiently and asymmetrically




A Bron, et al. The Ocular Surface 2009 Apr;7(2):78-92.
A Kerech, et al. Curr Eye Res 2013 Apr;38(4):428-36.

Rev B

CENTRE
FOR
SIGHT

Osmorality is the best single predictor of DED severity



Sullivan BD, et al. Invest Ophthalmol Vis Sci. 2010;51:6125-6130.

CENTRE
FOR
SIGHT

Tearlab - Discovery

- Osmolarity
- Interleukin-1 receptor antagonist (IL-1Ra)
- Matrix metalloproteinase 9 (MMP-9)

Indications	Asymptomatic	Symptomatic	P-values
Osmolarity (mOsm/L)	309.11±0.2	313.9±24.5	0.034
IL-1Ra (ng/ml)	279.3±50.9	342.3±472.9	0.566
MMP-9 (ng/ml)	100.51±131.0	339.11±565.5	0.058
TIBUT (ms)	10.11±4.5	8.38±4.5	0.078
CFS	0.41±0.8	0.6±1.0	0.289

Francesco Carones MD¹, Béatrice Cochever MD², Sheraz M. Daya MD³, Erik L. Mertens MD⁴, Thomas Kohnen MD, PhD, FEBD¹


CENTRE
FOR
SIGHT

OPD 3

Surface Regularity Index

Irregular astigmatism

Visual Potential



CENTRE
FOR
SIGHT

HD Analyzer

- Measures scatter
 - Tear film
 - Cornea
 - Lens
 - Vitreous




CENTRE
FOR
SIGHT



ASSESSMENT of findings

- SCORE components
- Assess underlying cause of each component



CENTRE
FOR
SIGHT

Management

GOALS

- Reduce symptoms
 - Lubricants – appropriate
- Treat underlying cause
- ? Treat Inflammation



CENTRE
FOR
SIGHT

MANAGEMENT

AQUEOUS DEFICIENT

- Sjogren's
- Non-Sjogren's
 - Drugs
 - Lacrimal Dysfunction
 - Lacrimal Gland Obstruction
 - Reflex Block – denervation (*Laser eye surgery*)

CENTRE
FOR
SIGHT

EVAPORATIVE

- Intrinsic
 - Meibomian Gland Dysfunction
 - Lid Closure – lagophthalmos
 - Blink Rate
- Extrinsic
 - Drug Preservatives
 - Ocular surface inflammation – allergy
 - CTL
 - Vitamin A deficiency



CENTRE
FOR
SIGHT

Meibomian Gland Disease

LID MARGINS

- Treat underlying lid problem
 - Seborrhea – Nizoral
 - Staph – Fucidic acid
 - Demodex – Tea Tree Oil



BlephEx™

CENTRE
FOR
SIGHT

Meibomian Gland Disease

- Lid Hygiene – Compresses and scrubs
- Inflamed ?
 - Lotemax BID for 3 months
- All should get Re-esterified Omega 3 (PRN Omega Eye)



CENTRE
FOR
SIGHT

What are Omega 3s ?


- Polyunsaturated Fatty Acids (PUFA)
 - DHA (Docoshexanoic Acid)
 - EPA (Eicosapantaneoic Acid)
 - DPA (Docospantaneoic Acid)
 - ALA (Alpha Linolenic Acid)
 - flax seeds
 - Requires conversion to EHA & DPA before active

CENTRE
FOR
SIGHT

'Dry Eye - Our approach...' (slides 33-48)

Why Re-esterified Omega 3?

CENTRE
FOR
SIGHT



Dose & Form

- > 2.7g - anti-inflammatory effect
- Arthritis Research & Therapy* 2006, 8:202 (doi:10.1186/ar1876)
- We can't get 2-3 grams of EPA & DHA from eating oily fish
- Better absorption in the body with rTG form



The bioavailability of EPA + DHA from reesterified triglycerides was superior (124%)

CENTRE
FOR
SIGHT

PERSONAL OBSERVATIONS

PRN Omega 3

- Schirmer's improves after 3 months
0mm to 4-5mm - !!!!!
- Blepharitis (Seborrheic, Demodex,) improves
- Telangiectasia less pronounced
- Turbid secretions – become Thinner & Clearer

? Poor Meibum causes low grade inflammation

CENTRE
FOR
SIGHT

Omega 3s and Prostatic Cancer ?

- Brasky et al. Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial.
 - Journal of the National Cancer Institute*
- Higher plasma levels of DHA & EPA associated with higher rate of prostate cancer

CENTRE
FOR
SIGHT

Omega 3s and Prostate Cancer

- Study measured plasma levels
 - Plasma levels fluctuate wildly depending on immediate intake
 - Red blood cell levels – medium term intake
- EPA + DHA Plasma levels between the two groups:
 - 4.48% no-cancer group
 - 4.66% in total cancer group
 - 4.66% in low grade CA
 - 4.71% in high grade CA

CENTRE
FOR
SIGHT

Omega 3s & Prostate Cancer

More studies that demonstrate a REDUCTION in Prostate CA with Omega 3

- Brasky TM, Kistal AR, Navarro SL, Lampe JW, Peters U, Patterson RE, White E. Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort. *Nutr Cancer* 2011;63:573-82.
- Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. *Am J Clin Nutr* 2010;92:223-33.
- Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A. Fatty fish consumption and risk of prostate cancer. *Lancet* 2001;357:1764-6.
- Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, Giovannucci EL. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancers. *Am J Clin Nutr* 2004;80:204-16.
- Mina K, Fritschl L, Johnson KC. An inverse association between preserved fish and prostate cancer: results from a population-based case-control study in Canada. *Nutr Cancer* 2008;60:222-6.
- Epstein MM, Kasperzyk JL, Mucci LA, Giovannucci E, Price A, Wolk A, Hakansson N, Fall K, Andersson SO, Andren O. Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. *Amer J Epidemiol* 2012;176:240-52.
- Fradet V, Cheng I, Casey G, Witte JS. Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. *Clin Cancer Res* 2009;15:2559-66. - See more at: <http://fplm.org/articles/heart-health/omega-3-fatty-acids-and-risk-for-prostate-cancer/#sthash.Ph2YRiqb.dpuf>

CENTRE
FOR
SIGHT

Meibomian Gland Disease

- Lipiflow
- MiboFlo
- Intense Pulsed Light



CENTRE
FOR
SIGHT


LipiFlow® Thermal Pulsation System

- Heat applied to the palpebral surfaces of the upper and lower eyelids directly over the meibomian glands
- Graded pulsatile pressure delivered to the outer eyelid



CENTRE FOR SIGHT

MiBoFlo



CENTRE FOR SIGHT

IPL - Lumenis M22



CENTRE FOR SIGHT

Evolved from treating Rosacea

- Rolando Toyos MD
- Discovered Rosacea patients - Dry eye improved



CENTRE FOR SIGHT

Treatment Protocol

- Treat from Ear to Ear
- Two pass protocol
- Closer to the Lid Margin the better the response
- More pigment in the skin the less energy needed
- Express after each treatment



CENTRE FOR SIGHT


IPL




CENTRE FOR SIGHT

Skin Rosacea

In skin rosacea, abnormal blood vessels release pro inflammatory agents
Those inflammatory agents propagate to the eyelids via the orbital vasculature*









Courtesy Rolando Toyos MD



CENTRE FOR SIGHT

'Dry Eye - Our approach...' (slides 33-48)



Meibomian Gland Disease

- Most common cause of dry eye
- Causes ?
- Principles of management:
 - Replace old oils
 - Reduce inflammation
- How ? – variety of methods...
 - Omega 3s
 - IPL

**CENTRE
FOR
SIGHT**

Thank you...



www.centreforesight.com

**CENTRE
FOR
SIGHT**

‘Dry Eye - Our approach...’ (slides 49-58)

Sheraz Daya
MD FACP FRCS(Ed) FRCOphth

**CENTRE
FOR
SIGHT**

